about
Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium.Cellular immunotherapies for cancer.Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15.CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell-Relevant Genes.Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB).CD69 is a direct HIF-1α target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes.Mitochondrial morphological and functional reprogramming following CD137 (4-1BB) co-stimulation.Cytokines in clinical cancer immunotherapyImmunotherapy of Cancer Visualized by Live Microscopy: Seeing Is BelievingTGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal AntibodiesImmunotherapeutic effects of intratumoral nanoplexed poly I:CRevisiting Interleukin-12 as a Cancer Immunotherapy AgentEpistatic Oncogenic Interactions Determine Cancer Susceptibility to ImmunotherapyExploiting TCR Recognition of Shared Hotspot Oncogene-encoded NeoantigensMetabolic Consequences of T-cell Costimulation in Anticancer ImmunityAn RNA toolbox for cancer immunotherapyRepurposing the yellow fever vaccine for intratumoral immunotherapyIntratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T CellsTwists and turns to translating 4-1BB cancer immunotherapyEngineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms
P50
Q38698632-3F5C1B17-BD26-4A11-BD4D-9942EA6A1C0BQ38722331-010259B2-C192-4831-87FA-BC4057A5B30EQ39389608-3BF604F7-ED75-45ED-B332-05756D24D566Q47225780-DAF98212-DD28-4A0A-B825-F3E0D4E8F90AQ47407440-43D3D1CB-4990-46FE-8D6F-06596075601FQ50200791-58A03847-0232-4977-B152-9F68BDF0099DQ50420978-146A4773-DB8B-47E7-B12D-FD0C7A8E1BB4Q50424224-5953478E-9993-4268-BD2F-4E096E59809BQ52717854-9513E91D-3326-4517-8A0F-424BE8D942FFQ58561585-A0D0347C-E2D6-43A5-9541-63BDD801552AQ59415939-8FC7C2CC-69C3-4277-BB18-E5965F8F8760Q63865741-8011A66C-07FA-45F7-8277-BAE9740642F3Q64071120-39B35FE8-4685-4538-BB04-B4F2E9E6A0E9Q88084895-EC2BF62C-B087-437A-B65D-9467E3503665Q89392336-5B71F59E-8568-4701-B2C7-3258017CCE0CQ89453077-CF22964F-FA21-4033-AC63-45F428CA5834Q90423361-8DF67581-34F5-44EF-9494-99F5497E4DB7Q91322503-E32C68F1-199C-482E-90C9-21DE05392016Q91349820-31270A97-3061-4F05-9FC5-B5420D70CE92Q91421884-F54F1037-1CE5-408F-B1A9-F5AEB623CAC4Q92689772-B909D931-7E0B-45F0-9302-B64D1E50CA82Q95319557-7F0B4071-CEBE-40FA-8107-4145919E50AE
P50
description
researcher
@en
wetenschapper
@nl
name
Iñaki Etxeberria
@en
Iñaki Etxeberria
@nl
type
label
Iñaki Etxeberria
@en
Iñaki Etxeberria
@nl
prefLabel
Iñaki Etxeberria
@en
Iñaki Etxeberria
@nl
P31
P496
0000-0003-2713-0836